OR WAIT null SECS
BD (Becton, Dickinson and Company) and Vancive Medical Technologies™, an Avery Dennison business, have launched a line of transparent vascular dressings with chlorhexidine gluconate (CHG) antimicrobial preservative that are designed to enhance patient care and be easy for clinicians to apply and remove.
The new BD ChloraShield™ dressings, which feature BeneHold™ CHG, an innovative adhesive technology from Vancive Medical Technologies, comfortably secure the dressing to the skin, absorb fluids and protect the site from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth, making them well-suited for catheter insertion sites. The Infusion Nurses Society recently released guidelines recommending the use of CHG dressings.1 BD is the exclusive distributor of the dressings worldwide.
"The combination of vascular access expertise from BD, infection prevention expertise from the CareFusion acquisition and CHG adhesive technology from Vancive Medical Technologies creates a powerful combination for a new vascular access product," said Stephen Hartley, global vice president of Infection Prevention for BD. "The new ChloraShield IV dressings complete BD's portfolio to offer a comprehensive set of products for vascular access procedures, including skin prep, catheters, connectors and flush products."
BD ChloraShield dressings are available in a variety of designs including bordered and non-bordered as well as sizes commonly used for peripheral IVs and PICCs.
"BeneHold CHG adhesive technology is well-suited for vascular access dressings," said Kirsten Newquist general manager for Vancive Medical Technologies. "The collaboration with BD brings together complementary expertise from both companies and we look forward to expanding the product offerings in the future."